Combination targeted therapy for relapsed FLT3-mutated leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of two targeted drugs, gilteritinib and momelotinib, for people whose acute myeloid leukemia (AML) has returned or has not responded to standard treatment. The drugs aim to block signals that help leukemia cells grow, potentially offering a new option for those with a FLT3 mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have been diagnosed with acute myeloid leukemia (AML) that has come back or has not responded to previous treatment.
- Your leukemia cells have a FLT3 gene change (either called FLT3-ITD or FLT3 D835/D836).
- You are not severely frail — your general health is within a certain range (ECOG performance status up to 3).
- Your liver and kidney function are within acceptable limits.
- You have not had chemotherapy or other experimental drugs in the last 7 days, unless you've recovered from side effects or your disease is rapidly growing.
- You are willing to use effective birth control during the study and for 4 months after finishing, if you can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This Phase 1/2 trial tests a combination of medicines (ASTX727, venetoclax, and gilteritinib) for adults with FLT3-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to see how well the treatment works and how safe it is for people whose disease has come back, is not responding, or (for some) is newly diagnosed.
This trial tests two targeted drugs, ziftomenib and quizartinib, together for people with a certain type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal is to find the best dose and see if the combination helps.
This trial tests a combination of two targeted drugs, SNDX-5613 and gilteritinib, for people whose AML has come back or hasn't responded to treatment. It is for those with an FLT3 gene mutation plus another specific genetic change like NPM1 or MLL. The study aims to see if this two-drug approach works better when used together.
This trial tests a three-drug combination for people with acute myeloid leukemia (AML) that did not respond to or came back after previous treatment with azacitidine and venetoclax. The goal is to see if adding gilteritinib can help control the leukemia.
This trial tests a new combination of drugs (gilteritinib plus a chemo regimen called FLAI) as the first treatment for adults with a specific type of acute myeloid leukemia (AML) that has a FLT3 mutation. The goal is to see if this combination helps destroy leukemia cells better and with acceptable side effects.
Hear when a new Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.